Esperion to Participate in Fireside Chat at the 36th Annual J.P. Morgan Healthcare Conference
January 03 2018 - 4:30PM
Fireside Chat Webcast on Wednesday, January 10,
2018 at 11:00 a.m. Pacific Time / 2:00 p.m. Eastern Time
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management
Company focused on developing and commercializing convenient,
complementary, cost-effective, once-daily, oral therapies for the
treatment of patients with elevated low density lipoprotein
cholesterol (LDL-C), today announced that president and chief
executive officer, Tim M. Mayleben, will participate in an
analyst-led fireside chat with investors at the 36th Annual J.P.
Morgan Healthcare Conference in San Francisco, CA on Wednesday,
January 10, 2018 at 11:00 a.m. Pacific Time / 2:00 p.m. Eastern
Time.
A live audio webcast of this event can be
accessed on the investor relations section of the Esperion website
at www.esperion.com. Replay of the webcast will be archived on
the Company's website for 90 days following the event.
Bempedoic Acid / Ezetimibe Combination Pill
Through the complementary mechanisms of action
of inhibition of cholesterol synthesis (bempedoic acid) and
inhibition of cholesterol absorption (ezetimibe), the bempedoic
acid / ezetimibe combination pill is our lead, non-statin, orally
available, once-daily, LDL-C lowering therapy. Inhibition of ATP
Citrate Lyase (ACL) by bempedoic acid reduces cholesterol
biosynthesis and lowers LDL-C by up-regulating the LDL receptor.
Inhibition of Niemann-Pick C1-Like 1 (NPC1L1) by ezetimibe results
in reduced absorption of cholesterol from the gastrointestinal
tract, thereby reducing delivery of cholesterol to the liver, which
in turn upregulates LDL receptors. Previously completed Phase 2
data demonstrated that this safe and well tolerated combination
results in a 48 percent lowering of LDL-C, a 26 percent reduction
in high sensitivity C-reactive protein (hsCRP), and may potentially
be associated with a lower occurrence of muscle-related side
effects.
Bempedoic Acid
With a targeted mechanism of action, bempedoic
acid is a first-in-class, complementary, orally available,
once-daily ACL inhibitor that reduces cholesterol biosynthesis and
lowers LDL-C by up-regulating the LDL receptor, and may potentially
be associated with a lower occurrence of muscle-related side
effects. Completed Phase 1 and 2 studies conducted in approximately
1,300 patients, and over 800 patients treated with bempedoic acid,
have produced clinically relevant LDL-C lowering results of up to
30 percent as monotherapy and an incremental 20+ percent when added
to stable statin therapy.
Esperion's Commitment to Patients with
Hypercholesterolemia
In the United States, 78 million people, or more
than 20 percent of the population, have elevated LDL-C; an
additional 73 million people in Europe and 30 million people in
Japan also live with elevated LDL-C. Esperion's mission as the
Lipid Management Company is to provide patients and physicians with
convenient, complementary, cost-effective, once-daily, oral
therapies to significantly reduce elevated levels of LDL-C in
high-risk patients with hypercholesterolemia, including patients
inadequately treated with current lipid-modifying
therapies. It is estimated that 40 million patients with
hypercholesterolemia in the U.S. are taking statins, approximately
12 million of those patients are at high-risk with atherosclerotic
cardiovascular disease (ASCVD) and/or heterozygous familial
hypercholesterolemia (HeFH) and with LDL-C that is not adequately
controlled despite receiving maximally tolerated lipid-modifying
background therapy. The 12 million high-risk patients include
patients only able to tolerate less than the lowest approved daily
starting dose of their statin and are considered statin intolerant.
Esperion-discovered and developed, bempedoic acid is a targeted
LDL-C lowering therapy in Phase 3 development. The company has two
bempedoic acid-based LDL-C lowering therapies in Phase 3
development: 1) a once-daily, oral bempedoic acid / ezetimibe
combination pill, and 2) bempedoic acid, a once-daily, oral
pill.
The Lipid Management Company
Esperion is the Lipid Management Company
passionately committed to developing and commercializing
convenient, complementary, cost-effective, once-daily, oral
therapies for the treatment of patients with elevated LDL-C.
Through scientific and clinical excellence, and a deep
understanding of cholesterol biology, the experienced lipid
management team at Esperion is committed to developing new LDL-C
lowering therapies that will make a substantial impact on reducing
global cardiovascular disease; the leading cause of death around
the world. Bempedoic acid and the company's lead product candidate,
the bempedoic acid / ezetimibe combination pill, are targeted
therapies that have been shown to significantly reduce elevated
LDL-C levels in patients with hypercholesterolemia, including
patients inadequately treated with current lipid-modifying
therapies. For more information, please
visit www.esperion.com and follow us on Twitter
at https://twitter.com/EsperionInc.
Media Contact:Elliot FoxW2O
Group212.257.6724efox@w2ogroup.com
Investor Contact:Mindy
Lowe Esperion734.887.3903mlowe@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Apr 2023 to Apr 2024